US OptionsDetailed Quotes
SGMT250117C10000
- 0.10
- 0.000.00%
15min DelayClose Dec 26 16:00 ET
0.00High0.00Low
0.10Open0.10Pre Close0 Volume396 Open Interest10.00Strike Price0.00Turnover186.78%IV98.82%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier22DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.1070Delta0.0792Gamma50.80Leverage Ratio-0.0097Theta0.0003Rho5.43Eff Leverage0.0023Vega
Sagimet Biosciences Stock Discussion
Sign in to post a comment
$Checkpoint Therapeutics (CKPT.US)$ $Ocean Power Technologies (OPTT.US)$ $ASP Isotopes (ASPI.US)$ $BitFuFu (FUFU.US)$ $Ondas Holdings (ONDS.US)$ $Unusual Machines (UMAC.US)$ $MKDWELL Tech (MKDW.US)$ $Sagimet Biosciences (SGMT.US)$ $Tonix Pharmaceuticals (TNXP.US)$ $WISeKey (WKEY.US)$ $U-BX Technology (UBXG.US)$ $Sidus Space (SIDU.US)$ $SEALSQ Corp (LAES.US)$
📊⚡️📊
📊⚡️📊
6
1
$Sagimet Biosciences (SGMT.US)$
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
Sagimet Biosciences presented Phase 2b data for denifanstat, its fatty acid synthase (FASN) inhibitor, at AASLD 2024. The FASCINATE-2 trial showed significant improvement in liver fibrosis in high-risk MASH patients, particularly in the F3 population where 49% of denifanstat-treated patients showed improvement versus 13% for placebo. AI-ba...
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
Sagimet Biosciences presented Phase 2b data for denifanstat, its fatty acid synthase (FASN) inhibitor, at AASLD 2024. The FASCINATE-2 trial showed significant improvement in liver fibrosis in high-risk MASH patients, particularly in the F3 population where 49% of denifanstat-treated patients showed improvement versus 13% for placebo. AI-ba...
5
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Sagimet Biosciences (SGMT.US)$
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
Ascletis Pharma has completed enrollment of 480 patients in its Phase III clinical trial of ASC40 (denifanstat), a once-daily oral tablet for treating moderate to severe acne. The randomized, double-blind, placebo-controlled trial began on January 24, 2024, with patients divided equally between treatment and placebo groups. The study will evalua...
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
Ascletis Pharma has completed enrollment of 480 patients in its Phase III clinical trial of ASC40 (denifanstat), a once-daily oral tablet for treating moderate to severe acne. The randomized, double-blind, placebo-controlled trial began on January 24, 2024, with patients divided equally between treatment and placebo groups. The study will evalua...
$Sagimet Biosciences (SGMT.US)$ Reuters· 3 mins ago
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions With FDA on the Development of Denifanstat for Mash; Phase 3 Program Initiation Expected by End of 2024
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions With FDA on the Development of Denifanstat for Mash; Phase 3 Program Initiation Expected by End of 2024
$Sagimet Biosciences (SGMT.US)$
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
Sagimet Biosciences Inc. (Nasdaq: SGMT) announced the publication of results from their Phase 2b FASCINATE-2 clinical trial of denifanstat in The Lancet Gastroenterology & Hepatology. The trial, conducted on patients with biopsy-confirmed metabolic-dysfunction associated steatohep...
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
Sagimet Biosciences Inc. (Nasdaq: SGMT) announced the publication of results from their Phase 2b FASCINATE-2 clinical trial of denifanstat in The Lancet Gastroenterology & Hepatology. The trial, conducted on patients with biopsy-confirmed metabolic-dysfunction associated steatohep...
$Sagimet Biosciences (SGMT.US)$ Nice to see a bit of a recovery🤫
2
16
$Sagimet Biosciences (SGMT.US)$
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in Mash
Sagimet Biosciences Inc. (Nasdaq: SCMT)
announced that the FDA has granted Breakthrough Therapy designation to denifanstat for treating noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.
This designation was supported by positive data from the Phase 2b FASCINATE-2 trial, where denifanstat showed statistically significant imp...
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in Mash
Sagimet Biosciences Inc. (Nasdaq: SCMT)
announced that the FDA has granted Breakthrough Therapy designation to denifanstat for treating noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.
This designation was supported by positive data from the Phase 2b FASCINATE-2 trial, where denifanstat showed statistically significant imp...
$Sagimet Biosciences (SGMT.US)$ Reuters· 3 mins ago
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in Mash
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in Mash
$Sagimet Biosciences (SGMT.US)$ Sagimet Biosciences Presented Data From FASCINATE-2 Phase 2B Trial Of Denifanstat Versus Placebo In Biopsy-Confirmed Metabolic Dysfunction-Associated Steatohepatitis Patients At The European Association For The Study Of The Liver Congress Benzinga · 4 mins Denifanstat achieved statistically significant results on primary and secondary liver biopsy endpoints in the ITT population, including both histology endpoints recommended in the FDA draft guidance for ac...
2
No comment yet
PaulG : SEALSQ to 5 in ?